GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis
Europe - Euronext Paris - EPA:ALGEN - FR0004053510 - Common Stock
2.5 EUR
-0.06 (-2.34%)
ALGEN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. ALGEN has only an average score on both its financial health and profitability. ALGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ALGEN had positive earnings in the past year.
ALGEN had a negative operating cash flow in the past year.
In multiple years ALGEN reported negative net income over the last 5 years.
In multiple years ALGEN reported negative operating cash flow during the last 5 years.
1.2 Ratios
ALGEN's Return On Assets of 3.31% is fine compared to the rest of the industry. ALGEN outperforms 78.31% of its industry peers.
With a decent Return On Equity value of 7.00%, ALGEN is doing good in the industry, outperforming 78.31% of the companies in the same industry.
The Return On Invested Capital of ALGEN (3.17%) is better than 74.70% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ALGEN is significantly below the industry average of 12.74%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.31% | ||
| ROE | 7% | ||
| ROIC | 3.17% |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
1.3 Margins
ALGEN has a Profit Margin of 6.14%. This is in the better half of the industry: ALGEN outperforms 78.31% of its industry peers.
ALGEN has a Operating Margin of 5.97%. This is in the better half of the industry: ALGEN outperforms 75.90% of its industry peers.
ALGEN's Gross Margin of 94.91% is amongst the best of the industry. ALGEN outperforms 91.57% of its industry peers.
ALGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.97% | ||
| PM (TTM) | 6.14% | ||
| GM | 94.91% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
2. Health
2.1 Basic Checks
ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALGEN has been reduced compared to 1 year ago.
Compared to 5 years ago, ALGEN has more shares outstanding
Compared to 1 year ago, ALGEN has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.75, we must say that ALGEN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ALGEN (1.75) is better than 68.67% of its industry peers.
ALGEN has a Debt/Equity ratio of 0.71. This is a neutral value indicating ALGEN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.71, ALGEN perfoms like the industry average, outperforming 48.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.75 |
ROIC/WACC0.45
WACC6.99%
2.3 Liquidity
A Current Ratio of 2.41 indicates that ALGEN has no problem at all paying its short term obligations.
The Current ratio of ALGEN (2.41) is comparable to the rest of the industry.
ALGEN has a Quick Ratio of 2.21. This indicates that ALGEN is financially healthy and has no problem in meeting its short term obligations.
ALGEN has a Quick ratio (2.21) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.21 |
3. Growth
3.1 Past
ALGEN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.46%.
ALGEN shows a decrease in Revenue. In the last year, the revenue decreased by -2.21%.
ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
3.2 Future
ALGEN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by 0.00% yearly.
ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.67, which indicates a correct valuation of ALGEN.
Compared to the rest of the industry, the Price/Earnings ratio of ALGEN indicates a rather cheap valuation: ALGEN is cheaper than 86.75% of the companies listed in the same industry.
ALGEN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.67 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALGEN is valued cheaper than 87.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 8.42 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.42%
EPS Next 3Y0%
5. Dividend
5.1 Amount
ALGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EPA:ALGEN (1/9/2026, 7:00:00 PM)
2.5
-0.06 (-2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners5.68%
Inst Owner ChangeN/A
Ins Owners7.91%
Ins Owner ChangeN/A
Market Cap23.70M
Revenue(TTM)20.95M
Net Income(TTM)1.29M
Analysts86.67
Price Target6.02 (140.8%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.67 | ||
| Fwd PE | N/A | ||
| P/S | 1.13 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.29 | ||
| P/tB | 1.91 | ||
| EV/EBITDA | 8.42 |
EPS(TTM)0.15
EY6%
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS2.21
BVpS1.94
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.31% | ||
| ROE | 7% | ||
| ROCE | 3.94% | ||
| ROIC | 3.17% | ||
| ROICexc | 3.17% | ||
| ROICexgc | 3.91% | ||
| OM | 5.97% | ||
| PM (TTM) | 6.14% | ||
| GM | 94.91% | ||
| FCFM | N/A |
ROA(3y)4.35%
ROA(5y)1.91%
ROE(3y)7.98%
ROE(5y)2.79%
ROIC(3y)5.56%
ROIC(5y)N/A
ROICexc(3y)6.94%
ROICexc(5y)N/A
ROICexgc(3y)9.99%
ROICexgc(5y)N/A
ROCE(3y)6.91%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.73%
GM growth 5Y0.4%
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.88 | ||
| Cap/Depr | 297.91% | ||
| Cap/Sales | 46.7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.41 | ||
| Quick Ratio | 2.21 | ||
| Altman-Z | 1.75 |
F-Score3
WACC6.99%
ROIC/WACC0.45
Cap/Depr(3y)64.02%
Cap/Depr(5y)125.45%
Cap/Sales(3y)10.32%
Cap/Sales(5y)17.64%
Profit Quality(3y)100.54%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.91%
EPS Next Y-100%
EPS Next 2Y-41.42%
EPS Next 3Y0%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.21%
Revenue growth 3Y16.31%
Revenue growth 5Y18.46%
Sales Q2Q%-10.34%
Revenue Next Year-7.14%
Revenue Next 2Y3.51%
Revenue Next 3Y10.37%
Revenue Next 5YN/A
EBIT growth 1Y-28.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year200%
EBIT Next 3Y68.69%
EBIT Next 5YN/A
FCF growth 1Y-380.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.89%
OCF growth 3YN/A
OCF growth 5YN/A
GENOWAY SA / ALGEN.PA FAQ
Can you provide the ChartMill fundamental rating for GENOWAY SA?
ChartMill assigns a fundamental rating of 5 / 10 to ALGEN.PA.
What is the valuation status of GENOWAY SA (ALGEN.PA) stock?
ChartMill assigns a valuation rating of 5 / 10 to GENOWAY SA (ALGEN.PA). This can be considered as Fairly Valued.
What is the profitability of ALGEN stock?
GENOWAY SA (ALGEN.PA) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for ALGEN stock?
The Price/Earnings (PE) ratio for GENOWAY SA (ALGEN.PA) is 16.67 and the Price/Book (PB) ratio is 1.29.
What is the financial health of GENOWAY SA (ALGEN.PA) stock?
The financial health rating of GENOWAY SA (ALGEN.PA) is 6 / 10.